lansoprazole has been researched along with Hemorrhage, Peptic Ulcer in 18 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer)." | 5.34 | Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. ( Chan, FKL; Ching, JYL; Chiu, PWY; Lau, JYW; Lau, LHS; Ling, RHY; Tse, YK; Wong, GLH; Wong, VWS, 2020) |
| " Group A was the treatment group, receiving lansoprazole OD 30 mg from a nasogastric tube for 14 days, while Group B, the control group, received no proton pump inhibitors or other medications for treating peptic ulcers." | 5.22 | Stress ulcer prophylaxis in patients being weaned from the ventilator in a respiratory care center: A randomized control trial. ( Chung, CS; Hsu, YL; Lee, TH; Lin, CC, 2016) |
| "to assess the safety and effectiveness of lansoprazole injection (Prosogan®) in patients with upper gastrointestinal bleeding due to peptic ulcers or erosive gastritis." | 5.17 | Safety and efficacy of lansoprazole injection in upper gastrointestinal bleeding: a postmarketing surveillance conducted in Indonesia. ( Setiawati, A; Syam, AF, 2013) |
| "Patients with high-risk bleeding peptic ulcers after successful endoscopic therapy were randomly assigned as oral lansoprazole or intravenous esomeprazole group." | 5.16 | Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. ( Lin, HJ; Soon, MS; Su, WW; Wu, SS; Yang, CW; Yen, HH, 2012) |
| "This analysis compared the efficacy of misoprostol, lansoprazole, and placebo in reducing the risk of gastric or duodenal ulcer recurrence in patients taking NSAIDs and low-dose aspirin." | 5.11 | Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. ( Amer, F; Christopoulos, NG; Goldstein, JL; Huang, B, 2004) |
| "Celecoxib was as effective as lansoprazole co-therapy in the prevention of recurrences of ulcer complications in subjects with a history of NSAID-related complicated peptic ulcers." | 5.11 | Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Sgourakis, G | 1 |
| Chatzidakis, G | 1 |
| Poulou, A | 1 |
| Malliou, P | 1 |
| Argyropoulos, T | 1 |
| Ravanis, G | 1 |
| Vagia, A | 1 |
| Kpogho, I | 1 |
| Briki, A | 1 |
| Tsuruhara, H | 1 |
| Stankovičová, T | 1 |
| Wong, GLH | 1 |
| Lau, LHS | 1 |
| Ching, JYL | 1 |
| Tse, YK | 1 |
| Ling, RHY | 1 |
| Wong, VWS | 1 |
| Chiu, PWY | 1 |
| Lau, JYW | 1 |
| Chan, FKL | 1 |
| Syam, AF | 1 |
| Setiawati, A | 1 |
| Lin, CC | 1 |
| Hsu, YL | 1 |
| Chung, CS | 1 |
| Lee, TH | 1 |
| Høie, O | 1 |
| Stallemo, A | 1 |
| Matre, J | 1 |
| Stokkeland, M | 1 |
| Lin, HJ | 2 |
| Kawano, S | 1 |
| Okada, H | 1 |
| Kawahara, Y | 1 |
| Hori, K | 1 |
| Tanioka, D | 1 |
| Tsuzuki, T | 1 |
| Inoue, M | 1 |
| Yagi, S | 1 |
| Takenaka, R | 1 |
| Yamamoto, K | 1 |
| Yen, HH | 1 |
| Yang, CW | 1 |
| Su, WW | 1 |
| Soon, MS | 1 |
| Wu, SS | 1 |
| Okamura, Y | 1 |
| Takeno, S | 1 |
| Takahashi, Y | 1 |
| Moroga, T | 1 |
| Yamashita, S | 1 |
| Kawahara, K | 1 |
| Cherniakevich, SA | 1 |
| Babkova, IV | 1 |
| Mikhalev, AI | 1 |
| Fedele, E | 1 |
| Goldstein, JL | 1 |
| Huang, B | 1 |
| Amer, F | 1 |
| Christopoulos, NG | 1 |
| Lai, KC | 2 |
| Chu, KM | 2 |
| Hui, WM | 2 |
| Wong, BC | 2 |
| Hu, WH | 2 |
| Wong, WM | 2 |
| Chan, AO | 2 |
| Wong, J | 2 |
| Lam, SK | 2 |
| Agustí-Escasany, A | 1 |
| Vallano-Ferraz, A | 1 |
| Inatomi, N | 1 |
| Nitta, K | 1 |
| Sakurai, Y | 1 |
| Otani, Y | 1 |
| Kitajima, M | 1 |
| Sugiyama, M | 1 |
| Watanabe, Y | 1 |
| Aoki, T | 1 |
| Bustamante, M | 1 |
| Stollman, N | 1 |
| Lau, GK | 1 |
| Yuen, MF | 1 |
| Lai, CL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial[NCT01180179] | Phase 4 | 228 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Oral vs Intravenous Proton Pump Inhibitor（PPI） in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial[NCT01123031] | Phase 4 | 0 participants (Actual) | Interventional | 2010-04-30 | Withdrawn (stopped due to The study was terminated and the PI has left the institution.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lansoprazole and Hemorrhage, Peptic Ulcer
| Article | Year |
|---|---|
High-dose vs. Low-dose Proton Pump Inhibitors post-endoscopic hemostasis in patients with bleeding peptic ulcer. A meta-analysis and meta-regression analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dose-Response Relationship, Drug; Female; Hemostasis, | 2018 |
[Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Gastric Acid; Gastric Mucosa; G | 2008 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; | 2000 |
9 trials available for lansoprazole and Hemorrhage, Peptic Ulcer
| Article | Year |
|---|---|
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antag | 2020 |
Safety and efficacy of lansoprazole injection in upper gastrointestinal bleeding: a postmarketing surveillance conducted in Indonesia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Drug | 2013 |
Stress ulcer prophylaxis in patients being weaned from the ventilator in a respiratory care center: A randomized control trial.
Topics: Aged; Aged, 80 and over; Female; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Peptic Ulcer | 2016 |
Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Cost-Benefit Analysis; Female; Gas | 2011 |
Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Administration, Oral; Aged; An | 2012 |
Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2004 |
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2005 |
Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Female; Gastric | 1995 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2002 |
6 other studies available for lansoprazole and Hemorrhage, Peptic Ulcer
| Article | Year |
|---|---|
Effect of oral lansoprazole on intragastric pH after endoscopic treatment for bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Aged, 80 and over; Anti-Ulcer A | 2009 |
Effect of oral lansoprazole on intragastric pH after endoscopic treatment for bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Female; Gastroscopy; Humans; Hydrogen-Io | 2009 |
Refractory ulcer of reconstructed gastric tube after esophagectomy: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Carcinoma, Squamous Cell; Cy | 2013 |
[Results of pre- and postoperative treatment of complicated duodenal ulcers with proton pump inhibitors ].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulce | 2002 |
[Is gastric and duodenal ulcer drug-treatable or surgical disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Humans; Lansoprazole; Om | 1997 |
[Gastric protection and treatment with low-dose aspirin].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |